Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual screening strategyArka Das, Ganesh Prasad Shenoy, Nahid Abbas et al.|Computational Toxicology|2022Cited by 12
Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancerPrasad Sanjay Dhiwar, Pujan Sasmal, Abhishek Ghara et al.|Medicinal Chemistry Research|2022Cited by 8